This page contains recent news articles, when available, and an overview of but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Background information on

www.streetinvesting.com: Market Review on Inhibitex Inc  -  Dec 17, 2007
Trading Markets (press release),...address cytomegalovirus infections, the Company has several development programs and collaborations based upon its proprietary MSCRAMM protein platform.

inhibitex to present at two investor conferences in november 2007  -  Oct 29, 2007
Business Wire (press release),...hiv integrase inhibitors, hcv polymerase inhibitors and a series of compounds to address cytomegalovirus infections, the company has several programs

Shareholders Approve Inhibitex Acquisition of FermaVir  -  Sep 20, 2007
Business Wire (press release),HIV integrase inhibitors, HCV polymerase inhibitors and a family of compounds to address cytomegalovirus infections, the Company has several programs

Hospitalization rates down for young kids with HIV  -  Aug 29, 2007
Scientific American...changes were observed in the number of hospitalizations for two other common opportunistic infections -- Pneumococcus or cytomegalovirus infections.

Biotest AG Biotest and Abbott  -  Aug 1, 2007
Ad-Hoc-News (Pressemitteilung),In individual cases Cytotect(TM) is therefore already used successfully in the treatment of cytomegalovirus infections in pregnant women,

New Clinical Results Increase Market Potential of Cytotect  -  Jul 16, 2007
PharmaLive.com (press release),Cytotect® is already successfully administered as a prophylaxis against cytomegalovirus infections (CMV) which occur following transplants.

Stealth Adapted Cytomegalovirus Infections as a Cause of Autism  -  Jul 2, 2007
24-7PressRelease.com (press release).../24-7PressRelease/ - BURBANK, CA, July 02, 2007 - The spate of publicity concerning human papillomavirus (HPV) infections coincides with the

Biotest AG Orphan drug status for  -  Jan 4, 2007
Ad-Hoc-News (Pressemitteilung),The decision of the US approval authority (FDA) ensures seven years' of exclusive market access to the treatment of cytomegalovirus infections in pregnancy.

FermaVir’s Founder and Board Member Professor Chris McGuigan ...  -  Nov 15, 2006
Business Wire (press release),FermaVir has licensed the technology produced in Professor McGuigan’s laboratory for the use in treatment in Shingles and Cytomegalovirus infections. ...

Search the web for more resources on

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.